Biopharmaceutical News and Research

RSS

Synageva receives $2.3 million under QTDP program

Synageva BioPharma Corp., a privately held biopharmaceutical company developing novel treatments for rare diseases, today announced that the US Treasury Department awarded approximately $2.3 million to Synageva BioPharma as part of the Qualifying Therapeutic Discovery Project Program.

4 Nov 2010

BioSpecifics receives $426,000 grant under QTDP Program

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that it has received $426,000 in grant funding under the Qualifying Therapeutic Discovery Project (QTDP) Program. The program, funded through the US Patient Protection and Affordable Care Act of 2010, supports therapeutic discovery programs.

4 Nov 2010

Vanda third quarter total revenue increases to $7.2 million

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the third quarter and nine months ended September 30, 2010.

3 Nov 2010

Insmed third quarter total revenues decrease to $1.8 million

Insmed Inc., a biopharmaceutical company, today reported results for the third quarter and nine-months ended September 30, 2010.

3 Nov 2010

Deloitte releases new report on innovative strategies for oncology drug development

Deloitte released a new report, "Innovative Strategies for Oncology Drug Development," highlighting specific drug development approaches that have enabled biotech companies to produce a substantial number of first-in-class compounds and more than $1 billion in oncology drugs while transforming the medical outlook for many cancer patients.

3 Nov 2010

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced today that it has established a Scientific Advisory Board to help advance the company's research and clinical studies in type 1 diabetes.

3 Nov 2010

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.

3 Nov 2010

NeurogesX initiates NGX-1998 Phase 2 study in postherpetic neuralgia

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced dosing of the first patient in its Phase 2 clinical study of NGX-1998, a liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).

3 Nov 2010

CytRx receives nontaxable grant under Qualifying Therapeutic Discovery Project Program

CytRx Corporation a biopharmaceutical company specializing in oncology, today announced that it has been awarded a nontaxable grant of approximately $735,000 related to its INNO-206, tamibarotene and bafetinib programs under the Qualifying Therapeutic Discovery Project Program included in the Patient Protection and Affordable Care Act, H.R. 3590, signed into law in March 2010.

3 Nov 2010

Nile announces results of CD-NP Phase 2 study in renally compromised ADHF patients

Nile Therapeutics, Inc. a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced results of its Phase 2 study evaluating its lead compound CD-NP in patients with acute decompensated heart failure (ADHF) and mild to moderate renal insufficiency. Study results demonstrated that multiple doses were characterized as well tolerated with favorable drug activity in this acute patient population.

3 Nov 2010

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has entered into a Cooperative Research and Development Agreement ("CRADA") with The Walter Reed Army Institute of Research.

2 Nov 2010

Soligenix completes enrollment in RiVax Phase 1B ricin toxin clinical trial

Soligenix, Inc., a late-stage biopharmaceutical company, reported today that it has completed enrollment of its Phase 1B clinical trial of RiVax™, a ricin subunit vaccine, in healthy volunteers. Preliminary results indicate that RiVax™ appears safe at all doses tested in volunteers. This trial is designed to assess the duration of immune responses using an adjuvant formulation of RiVax™ over a period of more than one year after vaccination.

2 Nov 2010

VaxInnate’s prototype flu vaccine named as Top 10 Infectious Diseases Projects to Watch in 2011

VaxInnate Corporation announced today that VAX125, its investigational prototype vaccine for seasonal flu, has been named one of the Top 10 Infectious Diseases Projects to Watch in 2011 by Elsevier Business Intelligence and the Windhover Conferences.

2 Nov 2010

Eli Lilly's new research center to focus on diabetes in China

Eli Lilly and Company announced today plans to open a research center focused on diabetes in China, where the incidence of the disease has reached epidemic proportions.

2 Nov 2010

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

BioCancell, a developer of anti-cancer drugs, announced success in attaining the goals of its Phase I/IIa clinical trial of BC-819 as a treatment for pancreatic cancer, which demonstrated an excellent safety profile and preliminary efficacy.

2 Nov 2010

Access Pharmaceuticals receives $1.5 million in government grants

ACCESS PHARMACEUTICALS, INC. a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has been awarded $1.5 million in government grants.

2 Nov 2010

PAREXEL first quarter revenue increases 13.9% to $295.8 million

PAREXEL International Corporation today announced its financial results for the first quarter ended September 30, 2010.

From Parexel 2 Nov 2010

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.

1 Nov 2010

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

As the champagne corks are popping this New Year's Eve, the first American Baby Boomers will turn age 65. Members of the demographic bulge that transformed American politics and culture are expected to usher in yet another momentous change a huge increase in the number of Alzheimer's disease patients.

1 Nov 2010

NeoPharm enters merger agreement with Insys Therapeutics

NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.

30 Oct 2010

Biopharmaceutical News and Research

Synageva receives $2.3 million under QTDP program

BioSpecifics receives $426,000 grant under QTDP Program

Vanda third quarter total revenue increases to $7.2 million

Insmed third quarter total revenues decrease to $1.8 million

Deloitte releases new report on innovative strategies for oncology drug development

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Immunomedics product candidates, technologies receive recognition from QTDP program

NeurogesX initiates NGX-1998 Phase 2 study in postherpetic neuralgia

CytRx receives nontaxable grant under Qualifying Therapeutic Discovery Project Program

Nile announces results of CD-NP Phase 2 study in renally compromised ADHF patients

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Soligenix completes enrollment in RiVax Phase 1B ricin toxin clinical trial

VaxInnate’s prototype flu vaccine named as Top 10 Infectious Diseases Projects to Watch in 2011

Eli Lilly's new research center to focus on diabetes in China

BioCancell's Phase I/IIa clinical trial of BC-819 shows positive result for pancreatic cancer

Access Pharmaceuticals receives $1.5 million in government grants

PAREXEL first quarter revenue increases 13.9% to $295.8 million

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

NeoPharm enters merger agreement with Insys Therapeutics

Event guide: World ADC San Diego eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News